Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity - Takeaways - MDSpire

Combination of Ixekizumab and Tirzepatide Results in Enhanced Disease Management Compared to Ixekizumab Monotherapy in Adults with Psoriatic Arthritis and Overweight or Obesity

  • By

  • Joseph F. Merola

  • Cynthia E. Kartman

  • Peter Fischer

  • Luna Sun

  • Anabela Cardoso

  • Mark C. Genovese

  • Alexis Ogdie

  • June 11, 2026

Share

  • 1

    Ixekizumab combined with Tirzepatide shows improved disease management in adults with Psoriatic Arthritis and overweight or obesity.

  • 2

    The study highlights the effectiveness of the combination therapy over Ixekizumab monotherapy.

  • 3

    Authors include experts from the University of Texas Southwestern Medical Center and Eli Lilly and Company.

  • 4

    The article has been accepted for publication and is undergoing peer review.

  • 5

    Disclosure forms for the authors are available, indicating potential conflicts of interest.

Original Source(s)

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

  • by Joseph F. Merola, Cynthia E. Kartman, Peter Fischer, Luna Sun, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie

  • June 11, 2026

Related Content

GLP-1 RAs May Ease Psoriasis, PsA Data Limited

Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.

A clinical care pathway for managing pregnancy in patients with inflammatory arthritis

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis